A 52-year-old male smoker with a 30 pack-year history presents with progressive dyspnea and chronic cough. Spirometry shows FEV₁/FVC ratio of 0.68 with FEV₁ at 45% predicted. Which investigation is most appropriate to confirm the diagnosis and assess disease severity?

Explanation

## Diagnosis and Rationale The spirometry pattern (FEV₁/FVC = 0.68, i.e., <0.70, with FEV₁ at 45% predicted) confirms **obstructive airway disease — COPD Stage III (Severe) per GOLD criteria** in this clinical context. The question asks for the investigation most appropriate to **confirm the diagnosis and assess disease severity**. The best answer is **DLCO measurement**. ### Why DLCO Over HRCT? **Key Point:** While HRCT chest is a valuable structural/imaging tool in COPD, it is **not the first-line functional investigation** after spirometry confirms obstruction. DLCO is the preferred next investigation because: 1. **Functional severity assessment:** DLCO directly quantifies alveolar-capillary surface area loss — the hallmark of emphysema — and correlates with exercise capacity, dyspnea severity, and mortality risk. 2. **Phenotyping:** DLCO differentiates **emphysema-predominant COPD** (reduced DLCO due to alveolar destruction) from **chronic bronchitis-predominant COPD** (normal or near-normal DLCO), guiding management intensity. 3. **GOLD guidelines:** DLCO is explicitly recommended as an add-on pulmonary function test after spirometry in COPD evaluation (GOLD 2023, Harrison 21e Ch 246). 4. **HRCT limitations:** HRCT exposes the patient to radiation, is expensive, and is reserved for specific indications — ruling out bronchiectasis, ILD overlap, lung cancer screening, or pre-surgical evaluation — not routine severity assessment. ### DLCO Interpretation in COPD | Finding | Interpretation | Clinical Significance | |---------|----------------|----------------------| | **Reduced DLCO** | Emphysema predominant | Alveolar destruction; higher mortality risk | | **Normal DLCO** | Chronic bronchitis predominant | Airway inflammation; relatively better prognosis | | **Severely reduced DLCO** | Extensive emphysema or ILD overlap | Aggressive management warranted | ### Why Not the Other Options? - **HRCT chest (A):** Structural imaging; useful for phenotyping and ruling out comorbidities, but not the primary functional severity tool. Not recommended routinely in uncomplicated COPD. - **6-minute walk test (C):** Assesses exercise tolerance and functional capacity; useful in rehabilitation planning but does not confirm diagnosis or directly assess pulmonary parenchymal severity. - **ABG analysis (D):** Indicated when FEV₁ <50% predicted *with clinical suspicion of hypoxemia/hypercapnia* or for oxygen therapy decisions — not the primary investigation for confirming diagnosis and assessing severity at this stage. **Clinical Pearl:** In a smoker with confirmed obstructive spirometry, DLCO is the **first add-on pulmonary function test** — it phenotypes the disease, predicts prognosis, and guides decisions on bronchodilator choice, pulmonary rehabilitation, and alpha-1 antitrypsin deficiency screening. **High-Yield:** DLCO is reduced in emphysema (alveolar destruction), normal in chronic bronchitis, and also reduced in ILD, pulmonary hypertension, and anaemia — making it a versatile severity marker beyond COPD alone. [cite: Harrison 21e Ch 246; GOLD 2023 Guidelines for COPD]